Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lund Hansen, R, Schoedt Jørgensen, T, Dreyer, L, Hetland, ML, Glintborg, B, Askling, J, Di Giuseppe, D, Jacobsson, LTH, Wallman, JK, Nordstrom, D, Aaltonen, K, Kristianslund, EK, Kvien, TK, Provan, SA, Gudbjornsson, B, Love, TJ & Kristensen, LE 2021, 'Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study', Rheumatology (Oxford, England), vol. 60, no. 1, pp. 140-146. https://doi.org/10.1093/rheumatology/keaa237

APA

Lund Hansen, R., Schoedt Jørgensen, T., Dreyer, L., Hetland, M. L., Glintborg, B., Askling, J., Di Giuseppe, D., Jacobsson, L. T. H., Wallman, J. K., Nordstrom, D., Aaltonen, K., Kristianslund, E. K., Kvien, T. K., Provan, S. A., Gudbjornsson, B., Love, T. J., & Kristensen, L. E. (2021). Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. Rheumatology (Oxford, England), 60(1), 140-146. https://doi.org/10.1093/rheumatology/keaa237

CBE

Lund Hansen R, Schoedt Jørgensen T, Dreyer L, Hetland ML, Glintborg B, Askling J, Di Giuseppe D, Jacobsson LTH, Wallman JK, Nordstrom D, Aaltonen K, Kristianslund EK, Kvien TK, Provan SA, Gudbjornsson B, Love TJ, Kristensen LE. 2021. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. Rheumatology (Oxford, England). 60(1):140-146. https://doi.org/10.1093/rheumatology/keaa237

MLA

Vancouver

Author

Lund Hansen, Rebekka ; Schoedt Jørgensen, Tanja ; Dreyer, Lene ; Hetland, Merete L ; Glintborg, Bente ; Askling, Johan ; Di Giuseppe, Daniela ; Jacobsson, Lennart T H ; Wallman, Johan K ; Nordstrom, Dan ; Aaltonen, Kalle ; Kristianslund, Eirik K ; Kvien, Tore K ; Provan, Sella A ; Gudbjornsson, Bjorn ; Love, Thorvadur J ; Kristensen, L E. / Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : a Nordic population-based cohort study. In: Rheumatology (Oxford, England). 2021 ; Vol. 60, No. 1. pp. 140-146.

Bibtex

@article{fa6b2fe997204087a908bcacb14df090,
title = "Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study",
abstract = "OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries.METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment.RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association.CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.",
keywords = "bDMARDs, international collaborations, prescription patterns, psoriatic arthritis, secular trends of inflammatory hallmarks",
author = "{Lund Hansen}, Rebekka and {Schoedt J{\o}rgensen}, Tanja and Lene Dreyer and Hetland, {Merete L} and Bente Glintborg and Johan Askling and {Di Giuseppe}, Daniela and Jacobsson, {Lennart T H} and Wallman, {Johan K} and Dan Nordstrom and Kalle Aaltonen and Kristianslund, {Eirik K} and Kvien, {Tore K} and Provan, {Sella A} and Bjorn Gudbjornsson and Love, {Thorvadur J} and Kristensen, {L E}",
note = "COPECARE",
year = "2021",
month = jan,
day = "1",
doi = "10.1093/rheumatology/keaa237",
language = "English",
volume = "60",
pages = "140--146",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics

T2 - a Nordic population-based cohort study

AU - Lund Hansen, Rebekka

AU - Schoedt Jørgensen, Tanja

AU - Dreyer, Lene

AU - Hetland, Merete L

AU - Glintborg, Bente

AU - Askling, Johan

AU - Di Giuseppe, Daniela

AU - Jacobsson, Lennart T H

AU - Wallman, Johan K

AU - Nordstrom, Dan

AU - Aaltonen, Kalle

AU - Kristianslund, Eirik K

AU - Kvien, Tore K

AU - Provan, Sella A

AU - Gudbjornsson, Bjorn

AU - Love, Thorvadur J

AU - Kristensen, L E

N1 - COPECARE

PY - 2021/1/1

Y1 - 2021/1/1

N2 - OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries.METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment.RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association.CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.

AB - OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries.METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment.RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association.CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.

KW - bDMARDs

KW - international collaborations

KW - prescription patterns

KW - psoriatic arthritis

KW - secular trends of inflammatory hallmarks

UR - http://www.scopus.com/inward/record.url?scp=85099428843&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keaa237

DO - 10.1093/rheumatology/keaa237

M3 - Journal article

C2 - 32591790

VL - 60

SP - 140

EP - 146

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 1

ER -

ID: 61799855